biospace.com

BMS’ Neuro Pipeline Rallied by Celgene Mega-Merger as Cobenfy Delays Persist

Bristol-Myers Squibb logoBristol-Myers Squibb
Sig1.70Sen-1.20Env0.00Soc0.00Gov0.00

Bristol Myers Squibb links its neuroscience “renaissance” to its $74 billion Celgene mega-merger in 2019, building a pipeline across schizophrenia, Alzheimer’s and multiple sclerosis. Cobenfy readouts for Alzheimer’s disease psychosis—after clinical trial setbacks—are now expected in 2027, with a possible interim analysis later this year. The company also highlights irafamdastat, a dual FAAH/MAGL inhibitor in Phase 2 for MS spasticity and Alzheimer’s agitation.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro